Platelet-activating factor-mediated contraction of rabbit lung strips: pharmacologic modulation.
Synthetic platelet-activating factor (PAF) (1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine, AGEPC) has been shown to induce a slowly developing contraction of rabbit lung parenchymal strips in an isolated organ bath. The spasmogenic effect of AGEPC appeared to be mediated by specific receptors distinct from H1, H2, cholinergic and C5a anaphylatoxin receptors. Prior exposure to AGEPC induced specific desensitization of lung parenchymal strips. Experiments with several pharmacological agents indicated that AGEPC-induced contraction was independent from cyclooxygenase, but was blocked when phospholipase A2 and lipoxygenase were inhibited and when the Ca++ channels were antagonized. Corticosteroids exhibited an inhibitory effect specific for AGEPC. Intracellular levels of cyclic AMP or cyclic GMP seemed to have a modulatory role in AGEPC-induced contraction of rabbit lung parenchymal strips.
D000109:Acetylcholine / Q000494:pharmacology; D000707:Anaphylaxis / Q000503:physiopathology; D000818:Animals; D003182:Complement C5 / Q000494:pharmacology; D015936:Complement C5a; D006632:Histamine / Q000494:pharmacology; D007073:Immunoglobulin E; D066298:In Vitro Techniques; D008168:Lung / Q000187:drug effects* / Q000502:physiology; D009119:Muscle Contraction / Q000187:drug effects*; D010972:Platelet Activating Factor / Q000494:pharmacology*; D011817:Rabbits
D003182:Complement C5; D010972:Platelet Activating Factor; D007073:Immunoglobulin E; D015936:Complement C5a; D006632:Histamine; D000109:Acetylcholine